EGFR and non-small cell lung carcinoma: Also, two EGFR inhibitors, afatinib and gefitinib, achieved better performance in non-small cell lung cancers (NSCLC) with mutated EGFR (P = 2.0 × 10− 7 and 6.6 × 10− 3).